The central dogma (basic assumption) of molecular biology is the assumption of the process of coding DNA, which contains the genetic material, transferring information to RNA and regulating protein synthesis according to the instructions in the code. Later, the concept of metabolites, i.e. products formed as a result of metabolic processes, was added when proteins begin to function by folding into active structures. In short, by adding the suffix -omic, the concepts that study these structures are derived. These are genomics, transcriptomics, proteomics, and metabolomics, respectively. However, later developments introduced the term “epi” into the literature, which plays a regulatory role without altering DNA, RNA, or protein sequences and is mostly dependent on environmental factors: Epigenomics, Epitranscriptomics, and Epiproteomics. The changes in these structures during normal and pathological processes have led to the acquisition of large amounts of data using high-throughput technologies. However, high performance information systems for analysis have not been able to be developed at the same pace. Information from a single omics analysis may not fully reflect the biological and clinical picture. Multi-omics data from multiple platforms, however, may offer significant potential for understanding the mechanisms underlying complex diseases and other clinical problems. New approaches to analyzing this Big Data have emerged, and the concept of multi-omics has entered the literature in recent years, allowing us to understand how they are affected by signal changes. In the coming years, healthcare will evolve from traditional methods to a process of “smart healthcare.” The 3 pillars of this process will be integrated multi-omics analysis (integrative multi-omics), personalized medicine (P-medicine), and artificial intelligence (AI). In this study, the developments, methods, and tools in the field of multi-omics analysis that are just starting to be talked about will be summarized.